Inhibition of the metalloprotease ADAM19 as a novel senomorphic strategy to ameliorate gut permeability and senescence markers by modulating senescence-associated secretory phenotype (SASP)

2025/03/20 by Sudipta Bar, Tyler Hilsabeck, Blaine Pattavina +8 · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Advanced biosensing and bioanalysis techniques #CRISPR and Genetic Engineering #Telomeres, Telomerase, and Senescence

paper · pdf · doi:10.18632/aging.206224

openalex publication_date 2025/03/20 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01

Abstract

Aging | doi:10.18632/aging.206224. Sudipta Bar, Tyler A.U. Hilsabeck, Blaine Pattavina, José Alberto López-Domínguez, Nathan Basisty, Joanna Bons, Mark Watson, Birgit Schilling, Judith Campisi, Pankaj Kapahi, Amit Sharma

Citations

• ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis
• Biomarkers for assessment of intestinal permeability in clinical practice

Discussions

• #AgingResearch: "Inhibition of the metalloprotease ADAM19 as a novel senomorphic strategy to ameliorate gut permeability and senescence markers by modulating senescence-associated secretory phenotype [bsky, 0 points, 0 comments]

Related

• The roles and mechanisms of senescence-associated secretory phenotype (SASP): can it be controlled by senolysis?
• Potential Regulators of the Senescence-Associated Secretory Phenotype During Senescence and Aging
• Cellular senescence: from pathogenic mechanisms to precision anti-aging interventions
• Blue period - features of senescence 30 years after beta-galactosidase
• Senolytics as Modulators of Critical Signaling Pathways: a Promising Strategy to Combat Brain Aging and Neurodegenerative Disorders